Novo CEO faces investor grilling after outlook hike soured by pipeline concerns

Novo Nordisk CEO Mike Doustdar faces investors and analysts on Wednesday under pressure to restore confidence in the drugmaker’s longer-term growth prospects after an upgraded 2026 outlook failed to reassure markets.